Strategic Diagnostics reports that it has received an initial order for genomic antibodies from a top ten pharmaceutical company
Scientists from this company require genomic antibodies to classes of proteins for which conventional antibody generation is typically unsuccessful.
These scientists have unsuccessfully attempted to make antibodies to some of the protein targets in this initial order, demonstrating the importance of these difficult targets in drug discovery and development and highlighting the potential for genomic antibodies to support their research.
A scientist at this company considers genomic antibodies technology to be part of the 'new frontier' of antibody generation.
As for all genomic antibodies orders, these scientists supplied only sequence information.
As a result, immunisation work begins before traditional peptide or protein antigens have been produced, purified, tested, and shipped to SDI.
Matthew Knight, president and CEO of Strategic Diagnostics, commented, "This initial order serves as a clear indication that world-class, diversified pharmaceutical companies are embracing our ability to provide Genomic Antibodies more quickly than conventional antibodies, while developing genomic antibodies to traditionally difficult antigen targets.
"This is the third major pharmaceutical customer to initiate a relationship with Strategic Diagnostics, and although these represent initially small projects, we are increasingly confident in the commercial viability of this capability.
"We are in the early phase of our commercial rollout, but the market reception has been exceptionally strong and significant conversations with customers are active.
"We continue to believe we bring significant value to our customers by decreasing the time to deliver new diagnostics and therapeutics to the market."
